Next results · Q4 2026Projected
Mar 29, before the open
Mon, Mar 29, 2027in 132 days
Projected from its last 8 releases. The company has not named the day yet.
- Quarter
- Q4 2026 · Ends about Dec 31, 2026
- 10-K window
- Mar 22 – Apr 6
Read against Q4 2025
The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.
- Revenue
- —
- Net income
- -$37.39M
- Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
- EPS
- —
- EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m
Results day
Typical moveA typical move of 5.1% either way
Up after 5 of 9, down after 4.
The stock’s move from the last close before each release to the first close after it, over the last 9 releases. Largest: +15.4% after Q3 2026.
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
When it reports
- Usual day
- Varies
- Session
- before the open
- After quarter end
- 41 to 86 days
- 10-Q filed
- 41 to 43 days
- over its last 7
- 10-K filed
- 86 to 89 days
- over its last 2
Based on 2 prior 10-K filings.
Bicara Therapeutics Inc. · CIK 2023658 · Engraved from SEC EDGAR